Sparse obesity market set to see six drugs launch by 2026

9 November 2018

The current obesity market is rather sparse, comprising of only six US Food and Drug Administration-approved drugs on the US market, two European Medicines-approved drugs in the top five European Union markets, and only one approved drug in Japan and two in China.

However, that is all likely to change, and a number of pharma majors are developing new anti-obesity drugs, including Novo Nordisk (NOV: N), Sanofi (Euronext: SAN) and AstraZeneca (LSE: AZN) and six drugs are expected to launch by 2026, according to data and analytics company GlobalData.

Dr Edit Kovalcsik, managing analyst at GlobalData, comments: “Obesity has become an epidemic and it is recognized as one of the major health issues due to the high risk of developing chronic diseases, such as cardiovascular disease and type 2 diabetes. It is now the most investigated indication within the metabolic disorders therapy area in the 8MM* by the number of trials."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK